Latest News and Press Releases

INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...

INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery,...

Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first...

GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc....

INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and...

Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555...

INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...

Register online today at: https://hub.pointbiopharma.com/investor-day-june-2023 INDIANAPOLIS, June 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”),...

PNT2004 program’s phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25th Poster to be available starting at 9:00 AM ET, June 3rd INDIANAPOLIS, May 25,...

INDIANAPOLIS and LANSING, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global...